Fibroid Mapping uses AI to standardize and streamline fibroid documentation by mapping, measuring, and classifying fibroids.
fetalHS simplifies and speeds fetal heart assessments by up to 48% by providing step-by-step, AI-driven guidance to help identify normal fetal heart anatomy.
In addition, a flexible wireless workflow is now a possibility with the integration of Vscan Air CL wireless dual probe with the new Voluson Signature systems, allowing for a wider range of motion because it is cable free.
“Next-level image clarity can help clinicians detect fetal abnormalities and hard-to-spot gynecological emergencies or conditions like endometriosis earlier, which can make a big difference in a patient’s treatment plan and overall health,” said Gerald Seifriedsberger, general manager, Women’s Health Ultrasound, GE HealthCare. “With proven time-saving AI-driven applications, and advanced automation features that simplify exams, we’re providing technology that can help enhance ease of use and provide clearer images – helping clinicians power through demanding workflows faster while delivering greater consistency and accuracy, ultimately helping deliver better health outcomes for women.”
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.
Back to HCB News
